CHARLES FURR: Open Payments
NPI 1295988517 · RUSTON, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$977 in 46 payments from 17 companies in 2025. Trend: 2023 $1,276 · 2024 $803 · 2025 $977
Food & beverage: $977
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 9 | $164 |
| AstraZeneca Pharmaceuticals LP | 2 | $136 |
| Vanda Pharmaceuticals Inc. | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $84 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $83 |
| ABBVIE INC. | 4 | $72 |
| Novo Nordisk Inc | 3 | $56 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $44 |
| Insulet Corporation | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
Products named: BREZTRI, NURTEC ODT, FANAPT, TRINTELLIX, CAPLYTA, REXULTI, PREVNAR 20, XIFAXAN.
Industry payments across LA — which companies pay providers there.
